KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Depreciation and Depletion (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Depreciation and Depletion for 8 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion rose 5.11% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2025, up 21.3% year-over-year, with the annual reading at $5.9 million for FY2025, 21.3% up from the prior year.
  • Depreciation and Depletion hit $1.5 million in Q4 2025 for Castle Biosciences, down from $1.5 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.5 million in Q3 2025 to a low of $233000.0 in Q1 2021.
  • Historically, Depreciation and Depletion has averaged $893350.0 across 5 years, with a median of $847000.0 in 2023.
  • Biggest five-year swings in Depreciation and Depletion: soared 270.59% in 2021 and later grew 5.11% in 2025.
  • Year by year, Depreciation and Depletion stood at $442000.0 in 2021, then soared by 41.86% to $627000.0 in 2022, then skyrocketed by 51.99% to $953000.0 in 2023, then surged by 49.84% to $1.4 million in 2024, then rose by 5.11% to $1.5 million in 2025.
  • Business Quant data shows Depreciation and Depletion for CSTL at $1.5 million in Q4 2025, $1.5 million in Q3 2025, and $1.5 million in Q2 2025.